Do you want to read an article? Please log in or register.
Duration of the efficacy of omalizumab after treatment discontinuation in 'real life' severe asthma
COMMENTED
Related content
RECOMMENDED
Asthma
Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Puggioni F, Brussino L, Canonica GW, Blasi F, Paggiaro P, Caminati M, Latorre M, Heffler E, Senna G, Severe Asthma Network in Italy (SANI) group.
doi: 10.2147/JAA.S274245
RECOMMENDED
Asthma
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Respir Med.
Bagnasco D, Brussino L, Bonavia M, Calzolari E, Caminati M, Caruso C, D'Amato M, De Ferrari L, Di Marco F, Imeri G, Di Bona D, Gilardenghi A, Guida G, Lombardi C, Milanese M, Nicolini A, Riccio AM, Rolla G, Santus P, Senna G, Passalacqua G
doi: 10.1016/j.rmed.2020.106080.
Asthma
Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study
J Asthma.
Albers FC, Müllerová H, Gunsoy NB, Shin JY, Nelsen LM, Bradford ES, Cockle SM, Suruki RY
doi: 10.1080/02770903.
Asthma
Real-life Efficacy of Omalizumab After 9 Years of Follow-up
Allergy Asthma Immunol Res.
Menzella F, Galeone C, Formisano D, Castagnetti C, Ruggiero P, Simonazzi A, Zucchi L
doi: 10.4168/aair.2017.9.4.368.
RECOMMENDED
Asthma
Clinical Determinants of Successful Omalizumab Therapy in Severe Allergic Asthma Patients: 4-Year-Long, Real-Life Observation
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Kucharczyk A, Więsik-Szewczyk E, Poznańska A, Jahnz-Różyk K
doi: 10.2147/JAA.S282203
Asthma
Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study
Allergy Asthma Immunol Res.
Li J, Kang J, Wang C, Yang J, Wang L, Kottakis I, Humphries M, Zhong N; China Omalizumab Study Group
doi: 10.4168/aair.2016.8.4.319.
AsthmaCOPD
Omalizumab Treatment Response in a Severe Allergic Asthma Population with Overlapping COPD
Chest.
Maltby S, Gibson PG, Powell H, McDonald VM
doi: 10.1016/
RECOMMENDED
Asthma
Treatment Eligibility of Real-life Mepolizumab-treated Severe Asthma Patients
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Allergy Clin Immunol Pract.
Richards LB, van Bragt JJMH, Aarab R, Longo C, Neerincx AH, Sont JK, Weersink EJM, Braunstahl GJ, Brinke AT, Bel EHD, Maitland-van der Zee AH
doi: 10.1016/j.jaip.2020.04.029.
Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety
Respir Med.
Mansur AH, Srivastava S, Mitchell V, Sullivan J, Kasujee I
doi: 10.1016/j.rmed.2017.01.008.